Golden logoGolden logo
Advanced Search
Locus Biosciences

Locus Biosciences

Locus Biosciences is a biotechnology company developing CRISPR-Cas3-engineered precision antibacterial products.

Locus Biosciences is a biotechnology company headquartered in Raleigh, North Carolina and was founded in 2015 by Charles Gersbach, Chase Beisel, Dave Ousterout, Nick Taylor, Paul Garofolo, and Rodolphe Barrangou.

Locus Biosciences develops CRISPR-engineered phage therapeutics, and uses Type I CRISPR-Cas3 system to destroy the DNA of target bacteria cells. Locus is the exclusive global licensee of the foundational CRISPR-Cas3 patent estate from North Carolina State University and Duke University. Although CRISPR-Cas9 is being used by a variety of companies to treat human diseases, Locus is the only company using CRISPR-Cas3 to tackle the problem of multidrug-resistant bacteria.

Locus's CRISPR-Cas3-engineered phage ("crPhage") platform is notable because it combines the safety profile of phages with the efficacy advantage of CRISPR. crPhage products kill target bacteria, including antibiotic-resistant superbugs, while leaving the many species of good bacteria in the body unharmed. The acquisition of EpiBiome's automation platform helps Locus develop these crPhage products to treat antibiotic-resistant bacterial infections and precisely edit the microbiome more rapidly.

Series A

On November 14, 2017 Locus Biosciences completed their series A funding round with $19 million in funding from Artis Ventures (lead investor), Starlight Ventures, North Carolina Biotechnology Center, and Abstract Ventures.


May 18, 2022
Locus Biosciences raises a $35,000,000 series B round from ARTIS Ventures and Viking Global Investors.
November 2020
Locus Biosciences raises a $12,500,000 grant from Carb-X.
August 2020
Locus Biosciences raises a $3,000 grant from North Carolina Biotechnology Center.
April 2020
Locus Biosciences raises a $20,000,000 venture round.
July 17, 2018
Acquisition of phage discovery platform

Locus Biosciences announced its acquisition of EpiBiome's high-throughput bacteriophage ("phage") discovery platform.

November 14, 2017
Series A - $19m

Locus closed $19m in series A funding. Led by Artis Ventures with backup from Tencent Holdings, Abstract Ventures and the North Carolina Biotechnology Centre, the first round fundraising is intended to fund through an IND filing and first clinical trial.

November 14, 2017
Locus Biosciences raises a $19,000,000 series A round.
Locus Biosciences was founded by Charles Gersbach, Chase Beisel, Dave Ousterout, Nick Taylor, Paul Garofolo and Rodolphe Barrangou.

Funding Rounds


Further Resources



Sophie Burkholder
March 8, 2021
Antibiotic resistance is one of the biggest potential threats to global health today. But Locus Biosciences is hoping that their crPhage technology might provide a new solution. Based in North Carolina's Research Triangle, the startup recently announced promising phase 1b clinical trial results for their use of CRISPR-Cas3-enhanced bacteriophages as a treatment for urinary tract [...]


Golden logo
By using this site, you agree to our Terms of Service.